Gapping up
In reaction to strong earnings/guidance: CYRX +1.7%, BNED +1%
M&A news: RLOC +170% (ReachLocal to be acquired by Gannett for $4.60/share),TEVA +1.7% (Mayne Pharma confirms agreement to acquire 37 approved and 5 FDA filed products from Teva and Allergan (AGN) for cash consideration of $652 mln),CI +0.5% (Anthem (ANTM) might soon walk away from CI M&A deal due to regulatory issues, according to NY Post)
Select financial related names showing strength: PUK +12.3%, LYG +6.5%, RBS +4.9%, DB +3.5%, BAC +3.4%, BCS+3.3%
Select metals/mining stocks trading higher: AKS +6.9%, FCX +5.6%, BBL +5.6%, CLF +4.9%, BHP +4.6%, RIO +4.4%,VALE +3.2%
Select oil/gas related names showing strength: CHK +5.7%, PBR +4.7%, OAS +3.9%, MRO +3.7%, RIG +3.5%, BP+3.1%, SDRL +2.8%, RDS.A +1.9%, TOT +1.7%
Other news: MRNS +8.9% (announces top-line data from a Phase 2 study to evaluateganaxolone for the treatment of anxiety and attention in children with Fragile X Syndrome), BPTH +8.8% (enters into a sponsored research agreement with Thomas Jefferson University to investigate DNAbilize), IMMU +6% (announces the issuance of the 28th patent covering the composition and uses of sacituzumab govitecan; updates on clinical development plan for sacituzumab govitecan in TNBC), DDD +4.5% (presenting at Die and Mould China 2016 conf today), LC +3.7% (names Scott Sanborn as CEO and President, discloses workforce reductions, updates on Q2 originations), MEET +3.6% (MeetMe to acquire Skout for $28.5 mln in cash & 5.37 mln common shares, implying an enterprise value of ~$54.6 mln, expects earnings accretion in first 12 months post-closing), VRX+3.3% (Director Ross disclosed purchase of 4000 shares, worth total of $97.6K (transaction date 6/13)), NVO +2.7% (receives EMA marketing authorization for authorisation of mylife YpsoPump for use with NovoRapid PumpCart), POT +2.5% (rebounding following yesterday's decline), AZN +2.4% (receives EC marketing authorization for Zavicefta), ZYNE +2.3% (announces 'positive' top line results from a Phase 1 trial of ZYN002 cannabidiol gel in development for the treatment of epilepsy, osteoarthritis and Fragile X Syndrome), "XRX +2.1% (Xerox announces agreement with Carl Icahn, will appoint Jonathan Christodoro to the Board effective immediately)," SCTY +2.1% (SolarCity announces formation of special committee to evaluate Tesla proposal; also, upgraded to Mkt Outperform from Mkt Perform at Avondale), SPLK +1.8% (Splunk announces that Groupon (GRPN) has agreed to a multi-year Enterprise Adoption Agreement for its Enterprise and Splunk Enterprise Security),TSLA +1.1% (SolarCity announces formation of special committee to evaluate Tesla proposal), TASR +1.1% (Jacksonville Sheriff's Office Deploys 2,500 TASER X26P Smart Weapons)
Analyst comments: VBLT +6.3% (initiated with a Buy at H.C. Wainwright; tgt $11), BT +6% (upgraded to Neutral from Underperform at Macquarie), RIO +4.4% (upgraded to Overweight from Equal-Weight at Morgan Stanley), AMAT +3.1% (upgraded to Neutral from Negative at Susquehanna), SHPG +2.7% (resumed on Conviction Buy List at Goldman)
Select metals/mining stocks trading lower: EGO -3.8%, HMY -3.2%, ABX -2.6%, GFI -2.6%, SLW -1.9%, HL -1.7%,NEM -1.6%, GOLD -1.5%, GDX -1.3%, AG -1%, AU -0.9%
Other news: RGLS -49.5% (receives verbal notice from the FDA that its IND for RG-101 for the treatment of chronic hepatitis C virus infection has been placed on clinical hold), SAND -9.3% (announces $50 mln bought deal financing at $4.45/share),BUFF -3% (Blue Buffalo commences secondary offering of 15 mln shares of its common stock on behalf of selling shareholders), SYT -1.3% (enters into global development and distribution agreement with The Stockton Group)
Analyst comments: MTOR -1.7% (downgraded to Underweight from Neutral at Piper Jaffray), MBLY -1.4% (downgraded to Neutral from Buy at Goldman), LB -1.2% (downgraded to Underperform from Neutral at BofA/Merrill), ATHM -0.6% (downgraded to Underperform from Neutral at Credit Suisse)
In reaction to strong earnings/guidance: CYRX +1.7%, BNED +1%
M&A news: RLOC +170% (ReachLocal to be acquired by Gannett for $4.60/share),TEVA +1.7% (Mayne Pharma confirms agreement to acquire 37 approved and 5 FDA filed products from Teva and Allergan (AGN) for cash consideration of $652 mln),CI +0.5% (Anthem (ANTM) might soon walk away from CI M&A deal due to regulatory issues, according to NY Post)
Select financial related names showing strength: PUK +12.3%, LYG +6.5%, RBS +4.9%, DB +3.5%, BAC +3.4%, BCS+3.3%
Select metals/mining stocks trading higher: AKS +6.9%, FCX +5.6%, BBL +5.6%, CLF +4.9%, BHP +4.6%, RIO +4.4%,VALE +3.2%
Select oil/gas related names showing strength: CHK +5.7%, PBR +4.7%, OAS +3.9%, MRO +3.7%, RIG +3.5%, BP+3.1%, SDRL +2.8%, RDS.A +1.9%, TOT +1.7%
Other news: MRNS +8.9% (announces top-line data from a Phase 2 study to evaluateganaxolone for the treatment of anxiety and attention in children with Fragile X Syndrome), BPTH +8.8% (enters into a sponsored research agreement with Thomas Jefferson University to investigate DNAbilize), IMMU +6% (announces the issuance of the 28th patent covering the composition and uses of sacituzumab govitecan; updates on clinical development plan for sacituzumab govitecan in TNBC), DDD +4.5% (presenting at Die and Mould China 2016 conf today), LC +3.7% (names Scott Sanborn as CEO and President, discloses workforce reductions, updates on Q2 originations), MEET +3.6% (MeetMe to acquire Skout for $28.5 mln in cash & 5.37 mln common shares, implying an enterprise value of ~$54.6 mln, expects earnings accretion in first 12 months post-closing), VRX+3.3% (Director Ross disclosed purchase of 4000 shares, worth total of $97.6K (transaction date 6/13)), NVO +2.7% (receives EMA marketing authorization for authorisation of mylife YpsoPump for use with NovoRapid PumpCart), POT +2.5% (rebounding following yesterday's decline), AZN +2.4% (receives EC marketing authorization for Zavicefta), ZYNE +2.3% (announces 'positive' top line results from a Phase 1 trial of ZYN002 cannabidiol gel in development for the treatment of epilepsy, osteoarthritis and Fragile X Syndrome), "XRX +2.1% (Xerox announces agreement with Carl Icahn, will appoint Jonathan Christodoro to the Board effective immediately)," SCTY +2.1% (SolarCity announces formation of special committee to evaluate Tesla proposal; also, upgraded to Mkt Outperform from Mkt Perform at Avondale), SPLK +1.8% (Splunk announces that Groupon (GRPN) has agreed to a multi-year Enterprise Adoption Agreement for its Enterprise and Splunk Enterprise Security),TSLA +1.1% (SolarCity announces formation of special committee to evaluate Tesla proposal), TASR +1.1% (Jacksonville Sheriff's Office Deploys 2,500 TASER X26P Smart Weapons)
Analyst comments: VBLT +6.3% (initiated with a Buy at H.C. Wainwright; tgt $11), BT +6% (upgraded to Neutral from Underperform at Macquarie), RIO +4.4% (upgraded to Overweight from Equal-Weight at Morgan Stanley), AMAT +3.1% (upgraded to Neutral from Negative at Susquehanna), SHPG +2.7% (resumed on Conviction Buy List at Goldman)
Gapping down
In reaction to disappointing earnings/guidance: EBF -3.6%
In reaction to disappointing earnings/guidance: EBF -3.6%
Select metals/mining stocks trading lower: EGO -3.8%, HMY -3.2%, ABX -2.6%, GFI -2.6%, SLW -1.9%, HL -1.7%,NEM -1.6%, GOLD -1.5%, GDX -1.3%, AG -1%, AU -0.9%
Other news: RGLS -49.5% (receives verbal notice from the FDA that its IND for RG-101 for the treatment of chronic hepatitis C virus infection has been placed on clinical hold), SAND -9.3% (announces $50 mln bought deal financing at $4.45/share),BUFF -3% (Blue Buffalo commences secondary offering of 15 mln shares of its common stock on behalf of selling shareholders), SYT -1.3% (enters into global development and distribution agreement with The Stockton Group)
Analyst comments: MTOR -1.7% (downgraded to Underweight from Neutral at Piper Jaffray), MBLY -1.4% (downgraded to Neutral from Buy at Goldman), LB -1.2% (downgraded to Underperform from Neutral at BofA/Merrill), ATHM -0.6% (downgraded to Underperform from Neutral at Credit Suisse)